COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 8 September 2021

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 14 July 2021

Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) adopted at PRAC meeting 3-6 May 2021

COVID-19 vaccine safety update for COVID-19 Vaccine Janssen: 11 May 2021

Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) adopted at PRAC meeting 20 April 2021

Human medicines European public assessment report (EPAR): Apidra, insulin glulisine, Date of authorisation: 27/09/2004, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Skyclarys, Omaveloxolone, Date of authorisation: 09/02/2024, Revision: 3, Status: Authorised

Substance and product data management services

Human medicines European public assessment report (EPAR): Buvidal, buprenorphine, Date of authorisation: 20/11/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Scemblix, asciminib, Date of authorisation: 25/08/2022, Revision: 7, Status: Authorised